Alto Neuroscience
ANRO
Market cap $61.7M

2.60 USD

+0.02

0.78%

At close Jul 11, 4:00 PM EDT

After hours

2.55

-0.05

1.92%

1 day

0.78%

5 days

11.11%

1 month

4.00%

3 months

22.07%

6 months

-38.82%

Year to date

-40.64%

1 year

-80.60%

5 years

-87.44%

10 years

-87.44%

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 76

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

8% more funds holding

Funds holding: 77 [Q4 2024] → 83 (+6) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

6.53% less ownership

Funds ownership: 83.54% [Q4 2024] → 77.01% (-6.53%) [Q1 2025]

21% less call options, than puts

Call options by funds: $50K | Put options by funds: $63K

33% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 27

53% less capital invested

Capital invested by funds: $95.3M [Q4 2024] → $45M (-$50.3M) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

54%

upside

Avg. target

$7

169%

upside

High target

$10

285%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio	285%upside $10	Buy Reiterated	26 Jun 2025
Wedbush Laura Chico	54%upside $4	Neutral Reiterated	15 May 2025

See Analyst Rankings

Financial journalist opinion

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). The study was conducted by the University of Oxford and was funded by the UK government's National Institute for Health and.

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept (POC) trial of ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. ALTO-203 is a novel, oral, h.

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally.

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025. ALTO-300, also known as agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist be.

Alto Neuroscience to Participate in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5th 2025: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Thurs.

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “In the first quarter of 2025 we took important steps to deliver on our clinical and corporate objectives,” said Am.

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at the Society of Biological Psychiatry (SOBP) Annual Meeting, in Toronto, Canada, held April 24-26, 2025. “The biological and clinical insights we presented at SOBP support our precision psychiatry pipeline and mark important advancements for.

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. The presentation will be accessible via a live webcast on the Events and Presen.

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage product candidates. “In 2024 we continued to advance our mission to change the way medicines are developed for neuropsychiatric conditio.

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Investigation Has Been Launched Into Alto Neuroscience, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm

See News Rankings

Charts implemented using Lightweight Charts™